1 / 4

Asia-Pacific Peripheral Neuropathy Treatment Market Trends, Size, Competitive An

Asia-Pacific peripheral neuropathy treatment market is estimated to grow at a CAGR of 5.1% during the forecast period. Rising incidences of diabetes is the major factor accelerating market growth.

Meenoo
Download Presentation

Asia-Pacific Peripheral Neuropathy Treatment Market Trends, Size, Competitive An

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Orion Market Research Asia-Pacific Peripheral Neuropathy Treatment Market, Size, Share, Analysis Report & Forecast to 2026 To Request a Sample of our Report on Asia-Pacific Peripheral Neuropathy Treatment Market: https://www.omrglobal.com/request-sample/asia-pacific-peripheral-neuropathy-treatment- market Company Name: Orion Market Research Contact Person: Mr. Anurag Tiwari Email: info@omrglobal.com Contact no: +91 780-304-0404

  2. Asia Asia- -Pacific peripheral neuropathy treatment market Pacific peripheral neuropathy treatment market is estimated to grow at a CAGR of 5.1% during the forecast period. A significant rise in cancer prevalence is one of the major factors accelerating the demand for peripheral neuropathy treatment in the region. As per the World Health Organization (WHO), the number of new cancer incidences in China was nearly 4.3 million in 2018. Additionally, the number of new cancer incidences in India was nearly 1.1 million in 2018. Chemotherapy is most often used for cancer treatment, which is significantly associated with the risk of developing chemotherapy- induced peripheral neuropathy (CIPN). Chemotherapy is used to destroy rapidly growing cancer cells in the body. The condition has been anticipated to be high in patients who received treatment with any neurotoxic chemotherapeutic agent. CIPN is normally treated with anticonvulsants, analgesics, and antidepressants. Topical agents including lidocaine are often used, and opioids can also be used in cases that involve extreme pain. (Get 15% Discount on Buying this Report) A full Report of Asia-Pacific Peripheral Neuropathy Treatment Market is Available at: https://www.omrglobal.com/industry-reports/asia-pacific-peripheral-neuropathy-treatment- market Scope of the Asia-Pacific Peripheral Neuropathy Treatment Market Market Coverage •Market number available for 2019-2026 •Base year- 2019 •Forecast period- 2020-2026 •Segment Covered- By Type and Application •Countries Covered- China, India, Japan, and Rest of Asia-Pacific •Competitive Landscape- Alembic Pharmaceuticals Ltd., Cipla Ltd., Daiichi Sankyo Company, Ltd., and Pfizer Inc. Recent Strategic Initiatives in the Asia-Pacific Peripheral Neuropathy Treatment Market •In April 2019, Daiichi Sankyo Company, Ltd. declared the launch of Tarlige tablets for pain treatment in Japan. In Japan 2019, ?2? ligand drug was approved in Japan for marketing based on phase 3 clinical trials results performed in Asia, for patients suffering from diabetic peripheral neuropathic pain, postherpetic neuralgia (PHN), for the treatment of peripheral neuropathic pain. •In July 2019, Cipla declared that InvaGen Pharmaceuticals, its subsidiary gained US approval for Pregabalin Capsules, which is intended for neuropathic pain management associated with some illnesses. InvaGen gained approval from the US FDA for the drug in the strengths of 25mg, 50mg, 75mg, 100mg, 150mg, 200mg, 225mg and 300mg. Key questions addressed by the report •What is the market growth rate? •Which segment dominates the market in the base year? •Which segment will project the fastest growth in the market? •How COVID-19 impacted the market? o Recovery Timeline o Deviation from the pre-COVID-19 forecast o Most affected segment •Who is the leader in the market? •How players are addressing challenges to sustain growth? •Where is the investment opportunity?

  3. To Request a Sample of our Report on Asia-Pacific Peripheral Neuropathy Treatment Market: https://www.omrglobal.com/request-sample/asia-pacific-peripheral-neuropathy-treatment- market Asia-Pacific Peripheral Neuropathy Treatment Market-Segmentation By Type •Antidepressants •Pain Relievers •Antiseizure •Others By Application •Diabetes •Chemotherapy-Induced •Others Asia-Pacific Peripheral Neuropathy Treatment Market– Segment by Country •China •India •Japan Rest of Asia-Pacific Company Profiles •Alembic Pharmaceuticals Ltd. •Bristol Myers Squibb Co. •Cipla Ltd. •Daiichi Sankyo Company, Ltd. •Eli Lilly and Co. •Glenmark Pharmaceuticals Ltd. •Lupin, Ltd. •Mylan N.V. •Novartis International AG •Pfizer, Inc. Reasons for Buying from us – 1. We cover more than 15 major industries, further segmented into more than 90 sectors. 2. More than 120 countries are for analysis. 3. Over 100+ paid data sources mined for investigation. 4. Our expert research analysts answer all your questions before and after purchasing your report. For More Customized Data, Request for Report Customization @ https://www.omrglobal.com/report- customization/asia-pacific-peripheral-neuropathy-treatment-market About Orion Market Research Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting and other research- based services.

  4. For More Information, Visit Orion Market Research Media Contact: Company Name: Orion Market Research Contact Person: Mr. Anurag Tiwari Email: info@omrglobal.com Contact no: +91 7803040404

More Related